Profile data is unavailable for this security.
About the company
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
- Revenue in INR (TTM)12.96bn
- Net income in INR1.62bn
- Incorporated1979
- Employees940.00
- LocationAstrazeneca Pharma India LtdNi 12Th Floor, Manyata Empassy BusinessPark Rachenahalli,Outer Ring Rd Kr PuramHebbalBANGALORE 560045IndiaIND
- Phone+91 8 067748000
- Fax+91 8 067748857
- Websitehttps://www.astrazeneca.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuland Laboratories Ltd. | 15.59bn | 3.00bn | 107.48bn | 1.65k | 35.82 | 8.38 | 29.87 | 6.90 | 233.89 | 233.89 | 1,214.81 | 999.78 | 0.9135 | 2.33 | 4.24 | 9,457,406.00 | 17.59 | 9.25 | 23.58 | 12.71 | 52.92 | 47.81 | 19.25 | 11.99 | 1.33 | 28.78 | 0.0692 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Jubilant Pharmova Ltd | 68.48bn | 5.53bn | 114.73bn | 1.03k | 20.77 | -- | 12.32 | 1.68 | 34.89 | 34.89 | 431.45 | -- | -- | -- | -- | -- | -- | 2.96 | -- | 3.55 | 68.13 | 69.37 | 8.01 | 5.13 | -- | 2.34 | -- | 24.69 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Caplin Point Laboratories Ltd | 16.94bn | 4.57bn | 116.10bn | 777.00 | 25.50 | 5.01 | 22.55 | 6.85 | 59.90 | 59.90 | 222.01 | 304.93 | 0.6931 | 2.22 | 3.62 | -- | 18.88 | 19.83 | 21.80 | 22.82 | 57.25 | 53.99 | 27.24 | 25.39 | 4.63 | 976.47 | 0.0008 | -- | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | -- |
| Wockhardt Ltd | 27.98bn | -4.63bn | 130.90bn | 2.39k | -- | 3.90 | -- | 4.68 | -32.08 | -32.08 | 194.04 | 218.97 | 0.365 | 1.80 | 3.95 | 11,687,550.00 | -6.16 | -4.56 | -11.11 | -8.29 | 58.36 | 55.26 | -16.87 | -12.70 | 0.5532 | -0.1594 | 0.3915 | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Granules India Ltd | 45.06bn | 4.05bn | 136.48bn | 4.12k | 33.67 | 4.23 | 22.28 | 3.03 | 16.72 | 16.72 | 185.99 | 133.08 | 0.8645 | 1.60 | 4.66 | 10,932,480.00 | 7.78 | 10.68 | 12.41 | 16.18 | 55.15 | 48.83 | 8.99 | 11.82 | 0.7444 | 6.13 | 0.2896 | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Eris Lifesciences Ltd | 20.09bn | 3.92bn | 146.08bn | 3.55k | 37.30 | 5.65 | 25.20 | 7.27 | 28.78 | 28.78 | 147.52 | 190.12 | 0.375 | 2.37 | 5.62 | -- | 7.41 | 13.42 | 11.22 | 16.80 | 81.08 | 80.29 | 19.76 | 24.96 | 0.8345 | 5.80 | 0.4633 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Sanofi India Ltd | 28.47bn | 5.49bn | 153.74bn | 2.17k | 28.00 | -- | 26.10 | 5.40 | 238.42 | 238.42 | 1,236.19 | -- | -- | -- | -- | 13,095,680.00 | -- | 22.42 | -- | 30.21 | 57.68 | 55.52 | 19.29 | 21.03 | -- | 442.82 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Concord Biotech Ltd | 10.17bn | 3.08bn | 178.12bn | 1.38k | 57.84 | 11.67 | 49.25 | 17.52 | 29.44 | 29.44 | 97.17 | 145.93 | -- | -- | -- | 7,385,180.00 | -- | -- | -- | -- | 77.46 | -- | 30.30 | -- | 4.84 | -- | 0.0063 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Astrazeneca Pharma India Ltd | 12.96bn | 1.62bn | 179.32bn | 940.00 | 111.02 | 25.19 | 101.62 | 13.84 | 64.60 | 64.60 | 518.21 | 284.77 | 1.26 | 2.84 | 9.79 | 13,782,230.00 | 15.66 | 11.78 | 24.44 | 19.62 | 54.11 | 54.64 | 12.47 | 10.27 | 1.97 | 141.26 | 0.0064 | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Piramal Pharma Ltd | 83.73bn | 277.60m | 219.71bn | 6.72k | 790.20 | -- | 28.19 | 2.62 | 0.2107 | 0.2107 | 64.75 | -- | -- | -- | -- | 12,462,350.00 | -- | -- | -- | -- | 64.15 | -- | 0.3315 | -- | -- | 7.12 | -- | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| Suven Pharmaceuticals Ltd | 10.51bn | 3.00bn | 236.35bn | 1.05k | 78.64 | 11.53 | 66.60 | 22.48 | 11.81 | 11.81 | 41.34 | 80.56 | 0.4983 | 1.64 | 8.58 | 9,993,856.00 | 14.23 | 23.17 | 15.19 | 26.20 | 57.34 | 58.85 | 28.56 | 33.21 | 9.64 | 47.59 | 0.0307 | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Natco Pharma Ltd. | 39.99bn | 13.88bn | 239.05bn | 3.98k | 17.27 | 4.08 | 15.18 | 5.98 | 77.30 | 77.30 | 222.76 | 326.99 | 0.6366 | 0.9929 | 3.91 | -- | 22.10 | 12.33 | 25.46 | 14.25 | 82.08 | 76.47 | 34.72 | 25.16 | 3.42 | 81.49 | 0.0596 | -- | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | -- |
| Alembic Pharmaceuticals Ltd | 62.29bn | 6.16bn | 239.09bn | 14.86k | 38.81 | 4.96 | 26.91 | 3.84 | 31.34 | 31.34 | 317.00 | 245.12 | 0.9865 | 1.10 | 6.01 | 4,192,105.00 | 9.75 | 10.72 | 12.92 | 14.25 | 72.46 | 65.98 | 9.89 | 12.47 | 0.9863 | 11.56 | 0.0963 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Pfizer Ltd | 21.93bn | 5.51bn | 239.87bn | 1.70k | 43.51 | 6.67 | 39.09 | 10.94 | 120.52 | 120.52 | 479.40 | 785.95 | 0.533 | 1.86 | 12.93 | -- | 13.40 | 14.22 | 15.69 | 17.71 | 63.86 | 61.79 | 25.14 | 24.05 | 4.27 | 37.18 | 0.0256 | 23.74 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Laurus Labs Ltd | 50.54bn | 1.48bn | 242.11bn | 6.01k | 163.72 | -- | 43.80 | 4.79 | 2.74 | 2.74 | 93.40 | -- | -- | -- | -- | 8,413,434.00 | -- | 10.13 | -- | 16.47 | 52.80 | 47.63 | 3.01 | 12.83 | -- | 2.04 | -- | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Emcure Pharmaceuticals Ltd | 66.58bn | 4.98bn | 245.33bn | 11.15k | 49.24 | 8.31 | 29.21 | 3.68 | 26.35 | 26.35 | 352.11 | 156.12 | 0.9197 | 1.70 | 3.78 | 5,973,669.00 | 7.29 | 7.14 | 13.30 | 13.93 | 61.02 | 59.29 | 7.92 | 7.81 | 0.8319 | 5.79 | 0.4279 | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
Data as of Jul 26 2024. Currency figures normalised to Astrazeneca Pharma India Ltd's reporting currency: Indian Rupee INR
7.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Jun 2024 | 727.59k | 2.91% |
| ICICI Prudential Asset Management Co. Ltd.as of 30 Jun 2024 | 382.04k | 1.53% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 245.20k | 0.98% |
| Bandhan Asset Management Co. Ltd.as of 30 Jun 2024 | 107.13k | 0.43% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 95.89k | 0.38% |
| SSgA Funds Management, Inc.as of 03 Jul 2024 | 78.28k | 0.31% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 50.06k | 0.20% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 30.34k | 0.12% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2024 | 21.91k | 0.09% |
| quant Money Managers Ltd.as of 28 Jun 2024 | 11.62k | 0.05% |
More ▼
Data from 31 Dec 2023 - 25 Jul 2024Source: FactSet Research Systems Inc.
